Effectiveness, Safety, and Patterns of Real-World Isavuconazole Use in Europe (2015–2019)
This study adds to the growing body of evidence that whether used as first-line therapy or after the failure of other antifungal therapies, isavuconazole appears to have a promising clinical response and a good safety profile as an antifungal agent in patients with varied underlying conditions.
Authors
- Dionysios Neofytos (ORCID: https://orcid.org/0000-0001-6970-2869)
- Cléa Melenotte (ORCID: https://orcid.org/0000-0003-3159-1061)
- Maria Fernandez (ORCID: https://orcid.org/0000-0002-8691-1328)
- David Enoch (ORCID: https://orcid.org/0000-0002-5433-0801)
- Raoul Herbrecht (ORCID: https://orcid.org/0000-0002-9381-4876)
- Maria Jimenez (ORCID: https://orcid.org/0000-0003-1626-9867)
- Olivier Lortholary (ORCID: https://orcid.org/0000-0002-8325-8060)
- Katherine Houghton (ORCID: https://orcid.org/0000-0003-4416-6080)
- Tobias Lahmer (ORCID: https://orcid.org/0000-0003-1008-5311)
- Francesco Giuseppe De Rosa (ORCID: https://orcid.org/0000-0001-8338-0130)
- Oliver A. Cornely (ORCID: https://orcid.org/0000-0001-9599-3137)
- Edward Broughton (ORCID: https://orcid.org/0000-0001-8621-7267)
- Antonio Pagliuca (ORCID: https://orcid.org/0000-0003-2519-0333)
- Carolina García‐Vidal (ORCID: https://orcid.org/0000-0002-8915-0683)
- Lili Jiang (ORCID: https://orcid.org/0000-0002-7628-237X)
- Beate Gruener
- Maria Lavinea Novis de Figueiredo Valente
Institutions
- Institut Pasteur (FR)
- Pfizer (United States) (US)
- University of Cologne (DE)
- King's College London (GB)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- Institut Necker Enfants Malades (FR)
- Institut de Cancérologie Strasbourg (FR)
- University Hospital of Geneva (CH)
- Hospital Clínic de Barcelona (ES)
- RTI Health Solutions (US)
- University Hospital Ulm (DE)
- University of Turin (IT)
- Technical University of Munich (DE)
- Université de Strasbourg (FR)
Publication Details
- Journal
- Infectious Diseases and Therapy
- Published
- 2024-10-24
- DOI
- https://doi.org/10.1007/s40121-024-01064-4
- Citations
- 5
- Primary Topic
- Antifungal resistance and susceptibility
- Type
- article
- Field-Weighted Citation Impact
- 1.95
Funders
- Pfizer